Amalgamated Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Amalgamated Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$475K	Buy	+19,593	New	+$474K	﹤0.01%	1533

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Amalgamated Financial's ACAD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2022: 19,593 shares worth $475K. The stake represents ﹤0.01% of the portfolio and ranks #1533 among its holdings.

263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

Amalgamated Financial held 19,593 shares of Acadia Pharmaceuticals worth $475K as of Q1 2022.
Acadia Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Acadia Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1533 holding.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.